Gary S. Stetz
Interim CEO, Director · Hepion Pharmaceuticals, Inc.
- 2025
- Aug 21, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Gary S. Stetz files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Vincent S. Lopriore - $750K in HEPA purchases and sales in the last 12 months
- Michael J. Purcell - $150K in HEPA purchases and sales in the last 12 months
- Sireesh Appajosyula - $150K in HEPA purchases and sales in the last 12 months
- Gary S. Stetz II - $25K in HEPA purchases and sales in the last 12 months
- Danina Fisher - $10K in HEPA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Gary S. Stetz?
Gary S. Stetz is a corporate insider, tracked as Interim CEO, Director of Hepion Pharmaceuticals, Inc. (HEPA). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Gary S. Stetz submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Gary S. Stetz been buying or selling stock?
Recorded transactions: 3 open-market purchases ($150K) and 8 open-market sales ($344K) across all tracked filings.
